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Background: In our previous studies, it was evident that the dichloromethane-methanol (1:1 v/v) stem barks extract
of Polyscias fulva and fractions (ethyl acetate, n-butanol and residue) demonstrated interesting antidermatophytic
activities. So, as a continuity of that, this work aimed at identifying active principles with antifungal properties from
P. fulva that could be used as markers for possible standardization of this plant as phytomedicine.
Methods: The ethyl acetate, n-butanol and residual fractions of the dichloromethane-methanol (1:1 v/v) stem
bark extract of Polyscias fulva were further fractionated by column chromatography and the structures of isolated
compounds elucidated based on their spectroscopic data in comparison with existing literature information.
Antifungal activity was assayed by broth microdilution techniques on yeasts and dermatophytes spores.
Results: The fractionation of the crude dichloromethane-methanol (1:1 v/v) stem bark extract of Polyscias fulva led
to the isolation of 10 known compounds (1 to 10) and one new saponin (11: 3-O-[α-L-rhamnopyranosyl (1–2)-α-L-
arabinopyranosyl]-28-O-[α-L-4-O-acetyl-rhamnopyranosyl (1–4)-β-D-glucopyranosyl-(1–6)-β-D-glucopyranosyl]-
hederagenin). Among these compounds, 3-O-α-L- arabinopyranosyl-hederagenin and 3-O-[α-L-rhamnopyranosyl
(1–2)-α-L-arabinopyranosyl]-hederagenin were the most active on the tested fungi with MIC values ranging from
0.78 to 100 μg/ml against both yeasts and dermatophytes.
Conclusion: The results of this work constitute a step forward in the possible development of an
antidermatophytic phytomedicine from Polyscias fulva stem bark, the isolated compounds being possible markers
for the standardisation.
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Exploring the healing power of plants is an ancient con-
cept. For many centuries people have been trying to
alleviate and treat diseases with different plant extracts
and formulations [1]. The interest in plants with anti-
microbial properties has been revived because of current
problems associated with the use of antibiotics [2]. The
fact that microorganisms among which fungi nowadays
tend to develop resistance towards drugs, coupled to the
undesirable side effects of certain antibiotics is a real* Correspondence: jrkuiate@yahoo.com
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unless otherwise stated.problem of concern. Medicinal plants constitute a prolific
source of antimicrobial substances. The valorization of
medicinal plants through the production of phytomedi-
cine implies the isolation of active compounds that can be
used in the standardization process of such drugs.
Polyscias fulva is a medium size and fast growing de-
ciduous tree of the tropical forests of sub-Saharan Africa
which is found at an altitude range of 1,180-2,500 m, with
annual rainfall of 1,500-2,000 mm [3]. In Cameroon, de-
coction of its bark is orally administered to cure venereal
infections [4] while paste from its stems barks and leaves
are used topically against dermatoses. In previous studies,
the dichloromethane extract from the bark of Polyscias
fulva appeared to possess a weak antiplasmodial againstl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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panosomial activities against Trypanosoma rhodesiense
(MIC = 100 μg/ml) [5]. Furthermore, its dichloromethane-
methanol (1:1 v/v) extract showed interesting in vitro and
in vivo antidermatophytic properties [6]. With the aim of
producing a standardized phytomedicine from the plant
species, the dichloromethane-methanol of the stem bark





The stem bark of Polyscias fulva (Hiern) was collected
in April 2008 at Bazou (Nde Division, West Region,
Cameroon). Botanical identification was done at the
Cameroon National Herbarium in Yaoundé by Mr
Tadjouteu Fulbert, where a voucher specimen was kept
under the reference number 43546/HNC.
Microorganisms
The antimicrobial activities of different substances were
carried out on seven yeasts and eleven dermatophytes.
Yeasts consisted of Candida albicans (ATCC 1663), C. kru-
sei (ATCC 6258), C. parapsilosis (ATCC 22019), C. lucita-
niae (ATCC 200950), C. glabrata (IP 35), Cryptococcus
neoformans (IP 95026) and Candida guilliermondii (clin-
ical isolate). Dermatophytes were made up of Microsporum
audouinii, Trichophyton rubrum, Trichophyton ajelloi and
Trichophyton equinum (clinical isolates) and Trichophyton
mentagrophytes (E 1425), Trichophyton terrestre (E 1501),
Microsporum gypseum (E 1420) and Epidermophyton floc-
cosum (E 1423); T. violaceum (CBS201.88), Microsporum
canis (CBS113480) and M. ferrugeneum (CBS457.80).
The references strains ATCC were obtained from the
American Type Culture Collection (Rockville, MD,
USA), IP from “Institut Pasteur” of Paris-France, E from
“Ecole Nationale Vétérinaire d’Aford” in France, CBS
from the Centraalbureau Voor schimmelcultures (Cen-
tral office for fungal cultures) in Netherlands, whereas
the clinical isolate were obtained from the Laboratory
of Bacteriology and Mycology of the “Centre Pasteur”
of Yaoundé-Cameroon. The strains have been maintained
in the refrigerator at 4°C on agar slant.
Phytochemical materials
Globally column chromatography (CC) was performed
on silica gel (80–120 and 200–300 mesh, Qingdao Marine
Chemical Co., China), Hp-20 (40–63 μm, Merck), and
Sephadex LH-20 (GE Healthcare, Sweden). TLC was per-
formed on HSGF254 (0.2 mm, Qingdao Marine Chemical
Co., China) or Rp-18 F254 (0.25 mm, Merck). Fractions
were monitored by TLC and spots were visualized by
heating silica gel plates sprayed with 10% H2SO4 in EtOH.Semipreparative HPLC was run on Agilent 1100 liquid
chromatograph with diode array detector (DAD), Zorbax-
SB-C18 column (5 μm; 25 cm × 9.4 mm i.d.).
UV spectra were measured using a Shimadzu UV-2401
PC spectraphotometer. IR spectra were obtained on Bruker
Tensor-27 infrared spectrophotometer with KBr pellets.
ESI-MS spectra were recorded on a Bruker HTC/Esquire
spectrometer, HRESIMS spectra were recorded on an API
Qstar Pulsar instrument. NMR, 1H-1H COSY, HMBC, and
HSQC experiments were performed on Bruker AM-400,
DRX-500, and Avance III 600 instruments with TMS as
the internal standard. Chemical shifts (δ) were expressed in
ppm with reference to the solvent signals.
Methods
Fractionation and isolation of active compounds from the
plant extract
The dichloromethane-methanol (1:1 v/v) extract (263 g)
from the stem bark of Polyscias fulva was pre-dissolved
in 250 ml of methanol and water (1:9) and shaken vigor-
ously in 500 ml of n-hexane. The n-hexane phase was
collected and the process repeated twice. The methanol
was then evaporated from the polar phase. The residue
obtained after methanol evaporation was partitioned in
the ethyl acetate and finally in the n-butanol as above.
The n-hexane, ethyl acetate and n-butanol phases were
concentrated under reduced pressure in a rotatory evapor-
ator to obtain 24.25 g of the n-hexane (09.22%), 23.77 g of
the ethyl acetate (09.03), 16 g of the n-butanol (06.08%)
and 195.98 g of the residual (74.52%) fractions after solv-
ent evaporation. The ethyl acetate, n-butanol and residual
fractions were fractionated by column chromatography.
Column fractionation of ethyl acetate fraction
20.77 g of ethyl acetate fraction was subjected to a silica
gel column (60×8.5 cm) chromatography eluted gradi-
ently with CHCl3–MeOH to give eight fractions [F1
(4.5 g), F2 (2 g), F3 (2.4 g), F4 (2.7 g), F5 (2.0 g), F6
(0.6 g), F7 (4.0 g), F8 (0.3 g)]. Antimicrobial activity was
concentrated in fractions F1 and F7 eluted with CH-Cl3
and CH-Cl3-MeOH (1:1) respectively. Further silica gel
column purification of F1 (42×3 cm) eluted with petrol-
eum ether-CHCl3 in a gradient elution mode and F7
(38x3 cm) eluted with CHCl3-MeOH in a gradient elu-
tion mode yielded five sub-fractions each denoted F1.1
to F1.5 and F7.1 to F7.5 respectively. F1.1 (135 mg), F1.5
(103 mg), F7.5 (2.62 g) were the most active against the
tested microorganisms and were then subjected to further
purification. Column purification of F1.1 (120 mg) on
Sephadex gel LH-20 (140×2.5 cm) with CHCl3-MeOH
(1–1) as eluting system afforded compound 2 (50 mg).
Purification of F1.5 (90 mg) was done through a Sephadex
column LH-20 (146x2.5 cm) and afforded compound 1
(16 mg). Fraction F7.5 (2.39 g) was further applied to
Njateng et al. BMC Complementary and Alternative Medicine  (2015) 15:25 Page 3 of 12chromatographic silica gel column (25×2cm) and eluted
with CHCl3-MeOH (25:75) to obtain 5 sub-fractions
(F7.5.1 to F7.5.5). F7.5.1, F7.5.2, F7.5.5, having anti-
microbial activity, were further purified. F7.5.1 (457 mg)
was purified on silica gel column (30×1.5 cm) with
CHCl3-MeOH (30:70) as eluting solvent. This purifica-
tion step afforded compound 3 (20 mg). Sub-fraction
F7.5.2 (378 mg) was subjected to preparative TLC plate
with CHCl3-MeOH (20:80) as eluting system and then
to Sephadex LH-20 column (120×1.5 cm) with CHCl3-
MeOH (10:90) as eluting system to afford compound 4
(50 mg). The sub-fraction F7.5.5 (504 mg) was applied
to chromatographic silica gel (80–120 μm) columns
(20x1.5 cm) and eluted with CHCl3-MeOH-H2O (30:69:1)
to obtain compounds 5 (29 mg) and 6 (19 mg).
Column fractionation of n-butanol fraction
The n-butanol fraction (13 g) of the crude dichlo
romethane-methanol (1:1 v/v) extract of P. fulva stem
bark was fractionated using a chromatographic column
HP 20 (60x8.5 cm) with MeOH-H2O (1:0→ 0:1 v/v)
followed by acetone. 25 fractions of 250 ml each were
collected and pooled into 4 major fractions (N1 to N4)
after evaporation in vacuum. Fractions N3 (7.10 g) and
N4 (3.09 g) presented antimicrobial activity and then
were subjected to further purifications.
N3 was subjected to silica gel column (74x4 cm) chro-
matography and eluted with EtOAc-MeOH (1:0→
0:1 v/v). Based on the TLC profiles in EtOAc-MeOH,
this afforded 7 sub-fractions (N3.1 to N3.7) of which
N3.5 (4.09 g) and N3.7 (2.1 g) were active against the mi-
croorganisms. N3.5 was then fractionated using Sephadex
LH-20 column (103×3 cm) with MeOH as eluting solvent.
A total of 142 fractions of 10 ml each were collected and
grouped into 4 sub-fractions (N3.5.1 to N3.5.4) based on
their thin layer chromatograms. N3.5.2 (2.64 g) was the
most active and was applied to silica gel (80–120 μm)
column (19×2 cm). It was eluted with EtOAc-MeOH
(1:0→ 0:1 v/v) and afforded 7 sub-fractions (N3.5.2.1 to
N3.5.2.7). Sub-fractions N3.5.2.1 (0.61 g), N3.5.2.2 (0.62 g)
and N3.5.2.6 (0.74 g) were biologically active. N3.5.2.1 was
applied to silica gel column (35×2 cm) and eluted in an
isocratic elution mode using EtOAc-MeOH (18:1). From
this, 4 sub-fractions (N3.5.2.1.1 to N3.5.2.1.4) were ob-
tained. Sub-fractions N3.5.2.1.1 and N3.5.2.1.3 were sub-
jected to gel permeation on Sephadex LH-20, and eluted
with MeOH to yield compounds 7 (40 mg) and 8 (52 mg)
respectively. N3.5.2.2 was applied to silica gel column
(40×2.5 cm) and eluted in an isocratic elution mode
using EtOAc-MeOH-H2O (18:5:1) to give 6 sub-fractions
(N3.5.2.2.1 to N3.5.2.2.6) based on their TLC profiles.
Subjected to Sephadex LH-20 column chromatography,
N3.5.2.2.2 gave compound 10 (103 mg). N3.5.2.6 (456 mg)
was also applied to silica gel column (45×2 cm), elutedwith EtOAc-MeOH-H2O 18:6:1, and gave 3 sub-fractions
(N3.5.2.6.1 to N3.5.2.6.3). N3.5.2.6.3 (236 mg) was further
purified by semi-preparative HPLC (MeOH-H2O, 25:75
v/v) to afford compound 11 (130 mg, Rt = 27.7 min).
Sub-fraction N3.7 was separated by MPLC or Medium
pressure liquid chromatography (Büchi pump manager
C-615) under the following conditions: pressure = 4.6 bar,
flow rate = 20 ml/min, time = 20 min, volume collected =
500 ml. This was eluted with H2O-MeOH (1:0→ 0:1 v/v)
to obtain 5 sub-fractions (N3.7.1 to N3.7.5). Among these
sub-fractions, N3.7.5 (509 mg) was bioactive and was ap-
plied to a silica gel column chromatography (CHCl3–
MeOH, 80:20 v/v) to give 89 sub-fractions of 10 ml each
grouped into 3 major sub-fractions (N3.7.5.1 to N3.7.5.3).
N3.7.5.3 (32 mg) was further subjected to Sephadex LH-
20 (103×1.5 cm) with MeOH as eluting system to give
compound 9 (12 mg).
N4 (3.09 g) was applied to silica gel column (45x3
cm), eluted with EtOAc-MeOH (1:0→ 0:1 v/v) to obtain
96 fractions of 300 ml each gathered into 14 sub-fractions
(N4.1 to N4.14). The most bioactive sub-fraction (N4.1,
750 mg), was applied to silica gel column (50×2 cm) with
EtOAc-MeOH (6:1) as eluent to give 4 sub-fractions
(N4.1.1 to N4.1.4). N4.1.4 (401 mg) was separated by
preparative silica gel plate using CHCl3-MeOH-H2O
(60:9:1 v/v/v) as eluting system to have 2 sub-fractions
(N4.1.4.1 and N4.1.4.2). 4.1.4.2 (207 mg) was applied to
silica gel column (30×2 cm) and eluted with CHCl3–
MeOH-H2O (240:9:1 v/v/v). 169 fractions were col-
lected, and grouped into 4 sub-fractions (N4.1.4.2.1 to
N4.1.4.2.4). Compounds 5 (11 mg) and 6 (13 mg) crys-
tallized from sub-fractions N4.1.4.2.2 and N4.1.4.2.4
respectively.
Column fractionation of residual fraction
The residual fraction (190.98 g) of the crude extract of
P. fulva stem bark was fractionated on a chromatographic
column HP 20 (70×8.5 cm) using MeOH-H2O (1:0→
0:1 v/v) as eluting system followed by acetone. 25 fractions
of 250 ml each were collected and pooled on the basis of
their TLC profiles (in EtOAc-MeOH-H2O) into 6 major
fractions (R1 to R6). After evaporation in vacuum, R6
(9.50 g) which was more active was subjected to further
purifications. Sub-fraction R6 was fractionated on a chro-
matographic column HP 20 (50×8.5 cm). Elution started
with H2O followed by gradual increases of MeOH to af-
ford 92 individual fractions (250 ml each) which were
grouped into eight collective fractions (R6.1 to R6.8).
Fraction R6.8 (1.03 g), which was the most bioactive,
was subjected to separation over silica gel (Sigma, 80–
120 μm) column (50×2.50 cm) using a gradient of CHCl3-
MeOH-H2O to give 6 main sub-fractions (R6.8.1 to
R6.8.6). Sub-fraction R6.8.1 (509 mg), the most bioactive,
was purified by silica gel column (50×2 cm), eluted with
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to give compound 10 (75 mg) from sub-fraction R6.8.1.2,
while sub-fraction R6.8.1.4 (76 mg) was chromatographed
on Sephadex LH-20 and eluted with MeOH to afford
compound 11 (40 mg).
Compound 1 is a white crystalline solid (Petroleum
ether); ESIMS: m /z 219 [M +Na]+, 197 [M +H]+; Mo-
lecular formula: C10H12O4;
13C -NMR (100 MHz,CDCl3); δ (ppm): 172.6 (1-C =
O); 163.1 (C- 2); 158.0 (C-4); 140.1 (C-6); 110.5 (C-5);
108.4 (C-1); 105.2 (C-3); 51.8 (MeO-C =O ); 24.1 (Me-
C6); 7.6 (Me-C3). NMR
1H (400 MHz, CDCl3); δ (ppm):
12.05 (s, 1H,); 6.21 (s, 1H, H-5); 3.92 (s, 3H, OCH3);
2.45 (s, 3H, −CH3); 2.10 (s, 3H, −CH3).
Compound 2 is in form of white needles (Petroleum
ether); m.p: 137–138°C; Molecular formula : C29H50O ;
1H-NMR (400 MHz,CDCl3), δ (ppm): 7.26 (s,OH-4);
5.35 (m, 1H, H-6); 3.53 (m,1H, H-3); 1.24 (s, 3H, H-19);
1.17 (s, 3H, H-18); 1.07 (s, 3H, H-26);1.01 (s, 3H, H-27);
0.92 (s, 3H, H-21); 0.90 (s, 3H, H-29).
13C-NMR (100 MHz, CDCl3) δ (ppm):140.7 (C-5);
121.7 (C-6); 71.8 (C-3); 56.7 (C-4); 50.1 (C-17); 45.8 (C-
14); 42.3 (C-13); 39.7 (C-10); 33.9 (C-20); 31.9 (C-25);
31.8 (C-26); 28.2 (C-23); 24.3 (C-12); 21.0 (C-18); 19.0
(C-21); 11.9 (C-27).
Compound 3 is a white powder (Cloroform); m.p:
119–120°C; ESIMS : m/z: 381 [M +Na]+; Molecular for-
mula : C20H22O6 ;
1H NMR (600 MHz, C5D5N); δ (ppm): 11.25 (s,
1H, −OH) ; 7.18 (m, 2H, H-6, 5); 7.16 (d, 1H, H-2);
4.95 (d, 1H, J =Hz); 4.35 (d, 1H, J =Hz ); 4.05 (d, 1H, J =
Hz ); 3.88 (3H, s, −OCH3);
13C-NMR (150 MHz, C5D5N)
(ppm): 149.3 (C-3); 133.6 (C-1); 120.2 (C-6); 116.9 (C-5);
111.3 (C-2); 86.9 (C-7); 72.4 (C-7’); 56.4 (C-8/8’); 55.3
(CH3O-C3).
Compound 4 is a white powder (Ethyl acetate); m.p.:
171–172°C; ESIMS: m/z 479 [M +Na]+; Molecular for-
mula: C30H48O3;
13C-NMR (150 MHz, CD3OD) δ (ppm): 182.1 (C-28);
145.4 (C-13); 123.8 (C-12); 79.7 (C-3); 56.9 (C-5); 48.7
(C-9); 47.8 (C-19); 47.4 (C-17); 43.0 (C-17); 42.9 (C-18);
40.7 (C-8); 40.0 (C-4); 39.9 (C-1); 38.3 (C-10); 35.0 (C-
21); 34.1 (C-29); 34.0 (C-22); 33.7 (C-7); 31.8 (C-20);
31.0 (C-23); 29.0 (C-23); 28.9(C-15); 28.0 (C-2); 26.5 (C-
27); 24.7 (C-11); 24.2 (C-16); 24.1 (C-30); 19.6 (C-6);
17.9 (C-24); 16.5 (C-26); 16.0 (C-25).
1H-NMR (600 MHz, CD3OD); δ (ppm): 5.24 (brs, 1H,
H-12); 3.19 (m, 1H, H-18); 2.83 (dd,7.2, 1H, H-3).
Compound 5 is a white amorphous powder (Ethyl
acetate); ESI MS: m/z 757 [M +Na]+; Molecular formula:
C41H66O11;
13C-NMR (150 MHz, CD3OD): 182.1(C-28); 145.2 (C-
13); 123.8 (C-12); 105.1 (C-1’); 102.2 (C-1”); 90.7 (C-3);
77.0 (C-2); 75.4 (C-16); 74.0 (C-4”); 73.4 (C-3’); 72.3 (C-3”); 70.4 (C-5”); 68.7 (C-4’); 64.1 (C-5’); 57.3 (C-5); 48.7
(C-9); 47.8 (C-19); 47.4 (C-17); 43.0 (C-17); 42.9 (C-18);
40.7 (C-8); 40.0 (C-4); 39.9 (C-1); 38.3 (C-10); 35.0 (C-
21); 34.1 (C-29); 34.0 (C-22); 33.7 (C-7); 31.8 (C-20);
31.0 (C-23); 29.0 (C-23); 28.9(C-15); 28.0 (C-2); 26.5 (C-
27); 24.7 (C-11); 24.2 (C-16); 24.1 (C-30); 19.6 (C-6);
17.9 (C-24); 16.5 (C-26); 16.0 (C-25).
Compound 6 is a white amorphous powder (Ethyl
acetate); ESIMS: m/z 773 [M +Na]+; Molecular formula:
C41H66O12;
13C-NMR (150 MHz, CD3OD): 145.2 (C-13); 123.6 (C-
12); 105.1(C-1’); 102.2 (C-1”); 90.7 (C-3); 76.9 (C-2); 75.4
(C-16); 74.0 (C-4”); 73.4 (C-3’); 72.3 (C-3”); 72.3 (C-2”);
70.3 (C-5”); 68.7 (C-4’); 64.1 (C-5’); 57.3 (C-5); 48.7 (C-
17); 48.3 (C-19); 47.8 (C-9); 42.8 (C-14); 42.2 (C-18);
40.8 (C-8); 40.4 (C-4); 40.1 (C-1); 38.1 (C-10); 36.7 (C-
15); 36.3 (C-21); 34.4 (C-29); 33.6 (C-7); 33.0 (C-22);
28.7 (C-23); 27.4 (C-27); 27.2 (C-2); 25.0 (C-30); 24.6 (C-
11); 17.9 (C-26); 17.2 (C-24); 16.3 (C-25).
Compound 7 is a white amorphous powder (Ethyl
acetate); ESIMS: m/z 479 [M +Na]+ ,441[M-CH3]
+ ; Mo-
lecular formula : C35H56O8 ;
13C NMR (100 MHz, MeOD); δ (ppm): 181.9 (C-26);
145.2 (C-13); 123.6 (C-12); 106.4 (C-1’); 83.3 (C-3); 74.5
(C-2’); 72.9 (C-3’); 69.8 (C-4’); 66.9 (C-5’); 64.8 (C-23);
49.6 (C-9); 48.6 (C-9); 48.4 (C-19); 48.1 (C-17); 47.6 (C-
5); 43.9 (C-4); 43.0 (C-14); 42.7 (C-18); 40.5 (C-1); 37.7
(C-10); 33.6 (C-22); 31.6 (C-20); 26.5 (C-27); 24.0 (C-16);
17.8 (C-26); 16.4 (C-25); 13.4 (C-24).
Compound 8 is a white amorphous powder (ethyl
acetate); °C; ESIMS: m/z 750 [M +Na]+; Molecular for-
mula: C41H66O12;
13C-NMR (125 MHz,C5D5N), δ (ppm): 181.8 (C-28),
145.3 (C-13), 123.0 (C-12), 104.4 (C-1’), 101.9 (C-1”),
82.1 (C-3), 76.6 (C-5’), 73.9 (C-4‘), 73.7 (C-4”), 72.2 (C-
5”), 72.0 (C-3’), 70.2 (C-2’), 70.0 (C-4”’), 64.9 (C-23), 48.6
(C-9), 48.4 (C-17), 47.6 (C-19), 43.9 (C-4), 43.9 (C-14),
42.9 (C-18), 40.4 (C-1), 37.6 (C-10), 33.6 (C-22), 31.6 (C-
20), 26.5 (C-27), 29.9 (C-16), 23.9 (C-11), 18.0 (C-6/6”),
17.8 (C-26), 16.4 (C-25), 13.9 (C-24).
1H NMR (500 MHz, C5D5N), δ (ppm): 5.23 (brs, H-12);
5.10 (s, H-1’); 4.57 (dd, 9.0, 7.4, H-2’); 3.77 (m, H-3”); 3.74
(H-5”); 3.70 (m, H-4”); 4.52 (m, H-2”); 3.44 (m, H-3’); 3.33
(brm, H-5’b); 3.51 (dd, 13.5, 3.5, H-18); 1.65 (sl H-1”); 1.10
(s, H-25); 0.95 (s, H-26); 0.81 (s, H-29); 0.75 (s, H-30).
Compound 9 is a white amorphous powder (Ethyl acet-
ate); C; ESIMS: m/z 831 [M+Na]+; Molecular Formula:
C43H68O14;
13C-NMR (125 MHz,C5D5N), δ (ppm): 177.0 (C-28),
171.4 (C-6’), 144.6 (C-13), 123.9 (C-12), 107.8 (C-1’),
96.2 (C-1”), 89.6 (C-3), 79.9 (C-3’), 79.4 (C-5’), 78.4 (C-
3”), 77.7 (C-5”), 75.9 (C-2”), 74.6 (C-2’), 73.2 (C-4’),71.5
(C-4”), 64.9 (C-23), 62.6 (C-6”), 52.6 (CH3O-C6’) 48.4
(C-9), 47.4 (C-17), 46.6 (C-19), 42.6 (C-4), 42.2 (C-14),
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(C-20 ), 28.7 (C-16), 26.6 (C-27), 23.8 (C-11), 18.9 (C-6);
17.9 (C-24); 17.4 (C-26); 16.0 (C-25).
1H NMR (500 MHz, C5D5N), δ (ppm): 6.36 (d, 10.4,
H-1”, 4.99 (d, 7.8, H-1”); 4.73 (dd, 9.0, 7.4, H-2’); 4.62
(m, H-4’); 4.57 (m, H-5”); 4.55 (m, H-4”); 4.42 (m, H-2”);
4.30 (m, H-3’); 4.27 (brm, H-5’b); 3.74 (dd, 13.5, 3.5, H-
18); 1.61 a (H-1”); 1.10 (s, H-25); 0.95 (s, H-26); 0.92 (s,
H-29); 0.86 (s, H-30).
Compound 10 is a white hite amorphous powder (Ethyl
acetate); ESIMS: m/z 1244 [(M +H) +Na]+; Formula:
C59H96O26;
13C-NMR (125 MHz,C5D5N), δ (ppm): 176.6 (C-28),
144.2 (C-13), 123.0 (C-12), 104.8 (C-1””), 104.2 (C-1’),
102.8 (C-1”), 101.7 (C-1””’), 95.7 (C-1”’), 78.7 (C-3), 77.2
(C-5”’), 76.6 (C-3”’), 76.0 (C-5’), 75.3 (C-2””), 74.2 (C-
2”’), 74.0(C-4‘), 73.9 (C-4”), 72.8 (C-5”), 72.6 (C-3’), 72.3
(C-2’), 70.0 (C-4”’), 69.8 (C-6”’), 65.1 (C-5’), 61.1 (C-23/
6”’), 48.2 (C-9), 47.8 (C-17), 47.1 (C-19), 43.5 (C-4), 43.5
(C-14), 42.2 (C-18), 40.0 (C-1), 37.0 (C-10), 33.1 (C-22),
30.8 (C-20), 26.1 (C-27), 23.9 (C-16), 23.8 (C-11), 18.5
(C-6/6”), 17.6 (C-26), 16.2 (C-25), 13.9 (C-24).
1H NMR (500 MHz, C5D5N), δ (ppm): 6.56 (d, 10.4,
H-1”); 6.30 (brs, H-1””’); 6.25 (d, 8.1, H-1”’); 5.38 (brs,
H-12); 5.10 (s, H-1’); 4.99 ( d, 7.8, H-1””); 4.98a (H-6a””);
4.73 (dd, 9.0, 7.4, H-2’); 4.70 (m, H-4”’/H-6”’); 4.66a ( H-
3”/H-2””’); 4.65a (H-3””’); 4.62a (H-4’); 4.59a (H-4””);
4.57a (H-5”); 4.55a (H-4”); 4.42a (H-2”); 4.38a (H-5””’);
4.34a (H-6””); 4.31a (H-4””’); 4.30a (H-3’); 4.27 (brm, H-
5’b); 4.17 (m, H-3””/H-5””); 4.10 (m, H-2””); 3.98 (m, H-
5”’); 3.95 (m, H-2”’); 3.74 (m, H-3”’); 3.51 (dd, 13.5, 3.5,
H-18); 1.70 (d, 6.4, H-6””’); 1.65 a (H-1”); 1.10 (s, H-25);
0.95 (s, H-26); 0.93 (s, H-29); 0.85 (s, H-30).
aUnresolved proton resonances.
Compound 11 is a white powder from AcOEt frac-
tion; m.p. 213–215°C; [α]D -38.9 (c 0.1, MeOH); IR
(KBr): υmax = 3428, 1731, 1642 cm
−1; HRESI-MS: 1285
[M+Na]+ (Calcd. for C61H98O27Na, 1285.6193); m/z =
1262; 1H and 13C NMR data are presented in Table 1.
Acid hydrolysis and GC analysis of compound 11
Two milligrams of compound 11 were refluxed with
2 M HCl (1, 4 dioxane/H2O 1:1, 2 ml) on water bath for
2 h at 95°C. After cooling, the reaction mixture was ex-
tracted with CHCl3 (3 × 5 ml). The aqueous layer was
evaporated to dryness with MeOH until neutral. The
dried residue was dissolved in 1 ml anhydrous pyridine
and treated with L-cysteine methyl ester hydrochloride
(1.5 mg) stirred at 60°C for 1 h. Trimethylsilylimidazole
(1.0 ml) was added to the reaction mixture, and kept at
60°C for 30 min.
The reaction mixture was analyzed by GC (Agilent
7890 A), under the following conditions: GC: FID. Col-
umn: HP-5 quartz capillary column (30 m × 0.32 mm).Column temperature: 100–230 with the rate of 10°C/
min, and the carrier gas was N2 (2 ml/min); injector
temperature: 250; split ratio: 1/20. The standard monosac-
charides were subjected to the same reaction and GC-MS
analysis. Under these conditions, the derivatives of D-
glucose, L-rhamnose and L-arabinose were detected at
10.942, 7.645, and 8.138 min respectively.
Preparation and standardisation of inocula
Preparation of yeasts inocula
Inoculum of each yeast was prepared from a 48 hours
Sabouraud Dextrose Agar culture. Isolated colonies from
this culture were diluted in 0.9% NaCl to match the 0.5
Mc Farland standard turbidity, corresponding to about
1.5 × 108 colony forming unit (CFU) per mL. This micro-
bial suspension was diluted to match the 0.09 optical
density at 600 nm corresponding to 2.5 × 105 spores.mL−1
using a Jenway 6105UV/Vis spectrophotometer (50 Hz/
60 Hz) [7].
Preparation of dermatophyte inocula
The inoculum of each dermatophyte was prepared from a
15 days old culture on Sabouraud Dextrose Agar (Conda,
Madrid, Spain). The culture surfaces were gently scraped
and introduced in test tubes containing 10 mL of sterile
saline, homogenized for 5 minutes and filtered. The ab-
sorbance of the spore suspensions (filtrates) were read at
530 nm and adjusted with sterile distilled water between
0.15 and 0.17 (Jenway 6105UV/Vis spectrophotometer,
50Hz/60Hz) to match 0.6 × 106 -1.4 × 106 CFU.mL−1 [8].
In vitro antimicrobial assay
The broth microdilution method [9] was used to deter-
mine the minimum inhibitory concentration (MIC) and
minimum fungicidal concentration (MFC) of the tested
substances using 96 well microplates (Nunclon, Roskilde,
Denmark). 96-well plates were prepared by dispensing
into each well 100 μL of Sabouraud Dextrose broth for
both yeasts and dermatophytes. A volume of 100 μL of
each test sample was added into the first wells of the
micro-titre plate. Serial two-fold dilutions of these test
samples were made. A volume of 100 μL of the above
standardized inocula was then added into each well to
match approximately 2.5×103 CFU.mL−1 for yeast and
104 CFU.mL−1 for dermatophytes in a total volume of
200 μL. This gave final concentration range of 0.1 to
0.00078 mg.mL−1 for compounds as well as for reference
drug (positive control). For every experiment, sterility
control (5% v/v aqueous DMSO and broth) and negative
control (broth plus inoculum) were included. The con-
tent of each well was mixed thoroughly and the micro
well plates were covered with the sterile lips and incu-
bated at 37°C for 48 h for yeasts and at 28°C for 5 days
for dermatophytes on a plate shaker (Flow Laboratory,
Table 1 1H NMR and 13C NMR data of compound 11 (400/100 MHz Pyridine-d5), δ in ppm, J in Hz
Position δC δH (J in Hz) Position δC δH (J in Hz)
1 39.9 3-ara-1’ 104.5 5.10 (1H, d, J = 6.2)
2 26.2 1.15 (2H, s) 2’ 76.9 4.43 (
3 81.1 4.24 (1H, d, J = 7.6) 3’ 73.9 4.10
4 43.5 4’ 69.5 4.29
5 47.7 5’ 65.8 3.68 (1H,s)
4.24 (1H, d, J = 4.0)
6 18.2 Rha-1” 102.2 6.21 (1H, s)
7 33.0 1.27 (1H, s) 2” 72.4 4.63 (1H, d, J = 3.3)
8 39.2 3” 72.6
9 48.2 4” 74.1 4.27 (1H, s)
10 36.8 5” 69.8 4.65 (2H, s)
11 23.8 6” 18.6 1.62 (3H, d, J = 4.7)
12 123.0 5.38 (1H, brs) 28-glu-1”’ 95.7 6.21 (1H, dl, J = 4.2)
13 144.2 2”’ 73.9
14 41.9 3”’ 79.9
15 21.8 2.25 (1H, s) 4”’ 70.8
1.04 (1H, s)
16 23.5 (2H, s) 5”’ 78.2 4.19 (1H, m)
17 46.1 6”’ 69.1 4.16 (1H, d, J = 9.1)
4.65 (1H, s)
18 42.2 3.14 (1H, d, J = 10.6) Glu-1”” 104.9 5.00 (1H, d, J = 7.8)
19 47.1 2”” 75.8
20 30.8 3”” 76.6
21 33.9 1.06 4”” 78.7
22 33.1 1.83 5”” 76.8 3.62 (1H, d, J = 9.4)
1.55
23 63.9 3.72 (1H,d, J = 7.9) 6”” 61.2 4.05 (1H, d, J = 3.4)
4.10 (3H, s) 4.18 (1H,d, J = 9.1)
24 14.1 1.03 (3H, s) Rha-1””’ 101.7 5.85 (1H, s)
25 16.3 0.94 (3H, s) 2””’ 72.5 4.71 (1H,brs)
26 17.6 1.09 (3H 3””’ 70.3 4.56 (1H, d, J = 2.2)
27 26.3 2.17 (1H, s) 4””’ 75.5 3.90 (1H, t, J = 8.4)
4.28 (1H, brs)
28 176.8 5””’ 67.5 5.02 (1H, s)
29 33.3 0.83 (3H, s) 6””’ 18.2 1.4 (3H, d, J = 4.7)
30 23.8 0.85 (3H, s) -C = O 170.9
-CH3 21.3 2.01 (3H, s)
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in each well was monitored by observing and comparing
the turbidity of the test wells to that of the positive and
negative controls. MIC was the lowest concentration of
the test substances that prevented visible growth of the
microorganisms.The MFC values were determined by subculturing
50 μL aliquots of the preparations, which did not show
any visible growth of the micro-organisms during MIC
determinations, into 150 μL of test substance-free SDB.
These preparations were further incubated as indicated
above. Microbial growth in each well was determined as
Njateng et al. BMC Complementary and Alternative Medicine  (2015) 15:25 Page 7 of 12mentioned above. MFC was the lowest concentration of
the test substances that prevented visible growth of the
microorganisms in the sub-cultures. All the experiments
were performed in triplicates.
Results
Structures of isolated compounds
Six compounds (1–6) were isolated from the ethyl acetate
fraction (Figure 1); five others (7–11) from the n-butanol
fraction, compounds 10 and 11 were also isolated from
the residual fraction. The isolated compounds belong to
various chemical groups but mainly triterpenoid saponins.
The structures of these compounds were established by
spectroscopic analysis [IR, ESI-MS, 1H and 13C NMR
spectra in conjunction with 2D experiments (1H-1H
COSY, ROESY, HMBC, and HSQC)] and direct compari-
son with published data. The compounds were identified
as: methyl 2,4-dihydroxy-3,6-dimethylbenzoate (Methyl
atrarate) (1) [10], β-sitosterol (2) [11], pinoresinol (3) [12],
oleanolic acid (4) [13], 3-O-[α-L-rhamnopyranosyl (1–2)-
α-L-arabinopyranosyl]-oleanolic acid or β-hederagenin (5)
[13], 3-O-[α-L-rhamnopyranosyl (1–2)-α-L-arabinopyra-
nosyl]-echinocystic acid (6) [14], 3-O-α-L- arabinopyra
nosyl-hederagenin (7) [15], 3-O-[α-L-rhamnopyranosyl
(1–2)-α-L-arabinopyranosyl]-hederagenin (8) [13], 3-O-
[methyl-β-D-glucurono-pyranosiduronoate]-28-O-β-D-
glucopyranosyl oleanolate (9) [16], 3-O-[α-L-rhamnopy
ranosyl (1–2)-α-L-arabinopyranosyl]-28-O-[O-α-L-rha
mnopyranosyl (1–4)-O-β-D-glucopyranosyl-(1–6)-β-D-




to be a new compound and fully describe bellow.
Structure elucidation of compound 11
Compound 11 was obtained as a white powder from
EtOAc, m.p. 213–215°C, [α]D -38,9 (c 0.1, MeOH) and
was positive to Liebermann-Burchard and Molish reaction
tests characteristic of triterpenoids and glycosides. The
molecular formula was established as C61H98O27 accord-
ing to HRESI-MS which showed a pseudomolecular ion
peak at m/z 1285. M +Na]+ (Calcd. for C61H98O27Na,
1285.6193). The IR spectrum also showed absorptions at
3428, 1731 and 1642 cm−1 accounting for hydroxyl, car-
bonyl and double bond, repectively. Anomeric proton sig-
nals in NMR spectrum at δ 5.10 (1H, d, J = 6.2 Hz, H-1’),
6.21 (1H, s, H-1”), 6.21 (1H, brd, J = 4.2 Hz, H-1”’), 5.00
(1H, d, J = 7.8 Hz, H-1””) and 5.83 (1H, s, H-1””’) together
with carbon signals at δ 104.5 (C-1’), 102.2 (C-1”), 95.7
(C-1”’), 104.9 (C-1””) and 101.7 (C-1””’) in the 13C NMR
spectrum suggested that compound 11 was a glycoside
with five sugar units. By comparing the NMR data with
those reported by Maillard et al. [17], 23-hydroxyoleanolic acid was also identified as the aglycone. Under
the conditions of acid hydrolysis and GC analysis, the de-
rivatives of D-glucose, L-rhamnose and L-arabinose were
detected at 10.942, 7.645, and 8.138 min respectively. By
comparing with the aglycone in the 13C NMR spectrum,
C-3 and C-28 were observed distinct down-field or up-
field shift respectively indicating that sugar moieties were
attached to these two positions. The data of the glyco-
side moieties are in agreement with those published by
Lu et al. [18] and were established as 3-O-α-L-rhamnopyr-
anosyl(1–2)-α-L-arabinopyranoside and 28-O-α-L-rham-
nopyronosyl(1–4)-ß-D-glucopyranosyl(1–4)-ß-D-gluco-
pyranosyde. The presence of an acetyl group was revealed
by the presence of two signals in the 13C NMR spectrum
at δ 170.9 and 21.3 which were respectively assigned to a
carbonyl group and a methyl, this assumption was further
confirmed by a signal in the 1H NMR at δ 2.01 (3H, s).
The relatively deshielded shift of C-4””’ of the L-
rhamnopyranosyl of the C-28 unit compare to that of C-
4” of the L-rhamnopyranosyl of the C-3 is due to the at-
tachment of the acetyl unit at this position. This informa-
tion was further supported by the long-range correlation
observed between H-4”” and this carbonyl group. The 1H
and 13C NMR data of compound 11 (Table 1) were
assigned on the basis of DEPT, 1H-1H COSY, HSQC and
HMBC experiment. Therefore, compound 11 (Figure 2)
was characterized as 3-O-α-L-rhamnopyranosyl(1–2)-α-L-
arabinopyranosyl-23-hydroxy oleanolic acid-28-O-α-L-4-O-
acetyl-rhamnopyranosyl(1–4)-ß-D-glucopyranosyl(1–6)-ß-
D- glucopyranoside or 3-O-[α-L-rhamnopyranosyl(1–2)-
α-L-arabinopyranosyl]-28-O-[α-L-4-O-acetyl-rhamno-
pyranosyl (1–4)-β-D-glucopyr anosyl- (1– 6)-β-D-gluco-
pyr ano syl]-heder ag enin (Figure 2).
Antifungal properties of compounds isolated from P.
fulva stem bark
The isolated constituents of P. fulva were screened for
their antifungal properties against 8 yeasts (7 Candida
species and Cyptococcus neoformans) and 11 dermato-
phyes (4 Microsporum, 6 Trichophyton and 1 Epidermo-
phyton) (Table 2). Compounds 7 and 8 were relatively
active against all the tested yeasts while 2, 3 and 9 were to-
tally inactive. The antifungal properties of the other com-
pounds were selectively observed on some yeasts. All the
tested substances showed a wide range of antidermatophy-
tic activities, inhibiting the growth of almost all the tested
dermatophytes (Table 2). Compounds 10 and 11 (MIC
generally greater than 50 μg/ml) appeared to be the less
actives among all. Compounds 1–3 expressed relatively
good antidermatophytic activities against M. ferrugeneum,
M. audouinii, T. violaceum and E. flocossum. Compounds
4 and 5 were the most efficient in inhibiting the dermato-
phytes growth. Compounds 7 and 8 showed intermediate
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Figure 1 Chemical structures of compounds isolated from the stem barks of P. fulva.












































Figure 2 Structure and key HMBC correlations of compound 11.
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drug Griseofulvin on selected microorganisms.
Discussion
The isolated compounds globally demonstrated more or
less interesting antifungal activities. They were phenolics
(1 and 3), steroids (2), triterpene (4) and terpenoid sapo-
nins (5–11) secondary metabolites. Most of the antimicro-
bial substances isolated from Cameroonian medicinal
plants belong to these chemical groups [19]. Up to 7 of
the 11 isolated compounds from P. fulva were terpenoid
saponins; such substances with hederagenin or oleanolic
acid as aglycone have been found to possess antifungalactivities against yeasts and filamentous fungi [20]. Saponins
possess the ability to bind with sterols in fungal membrane
and cause pore formation and loss of membrane integrity
[21] as antifungal of polyene group [22]. Structure-activity
relationship of these types of compounds has been demon-
strated and their antifungal properties depend on the num-
ber and type of sugar residues, but the increase in sugar
length does not enhance the activity [21]. The anti-yeasts
activities of saponins 7 and 8 (the only active compounds
on yeasts) compared to compounds with the same basic
skeleton (4–6 and 9–11) could be ascribed to the presence
of a hydroxyl group at position 23 coupled to the presence
of a free carboxyl group at position 28. In contrast, all these
Table 2 MICs/MFCs (μg/ml) of isolated compounds on tested yeasts and dermatophytes
Fungi 1 2 3 4 5 6 7 8 9 10 11 Nyst or Gri
Yeasts
C. albicans (ATCC 1663) −/− −/− −/− −/− 100/- 50/- 100/- 12.5/25 −/− −/− −/− 0.04/0.08
C. Glabrata (IP 35) −/− −/− −/− 12.5/100 −/− −/− 12.5/25 12.5/12.5 −/− 100/- 25/100 0.02/0.02
C. Lucitaniae (ATCC 200950) −/− −/− −/− −/− −/− −/− 50/50 50/50 −/− −/− −/− 0.02/0.08
C. Parapsilosis (ATCC 22019) −/− −/− −/− −/− −/− −/− 100/100 50/100 −/− −/− −/− 0.01/0.08-
C. guilliermondii −/− −/− −/− 12.5/- −/− 12.5/- 12.5/25 12.5/12.5 −/− 100/- 50/- 0.02/0.08
C. Krusei (ATCC 6258) −/− −/− −/− −/− −/− −/−−/− 100/100 25/50 −/− −/− −/− 0.04/0.08
Cryptococcus neoformans (IP 95026) 100/- −/− −/− −/− −/− −/− 12.5/100 6.25/50 −/− 6.25/- −/− 2.00/2.00
Dermatophytes
T. ajelloi −/− 6.25/12.5 6.25/12.5 6.25/12.5 0.78/1.56 200/200 12.5/12.5 6.25/12.5 200/- 100/- 50/50 0.31/0.31
T. terrestre (E 1501) 100/- 3.12/12.5 3.12/6.25 3.12/6.25 3.12/6.25 −/− 12.5/50 12.5/12.5 100/100 −/− 50/50 50/100
T. equinum 100/- 100/- 100/- 6.25/100 −/− −/− 50/100 25/50 100/- 50/100 100/100 0.31/0.31
T. mentagrophytes (E 1425) 100/- 100/- 100/- 6.25/100 −/− −/− 25/25 12.5/25 100/- 50/100 100/100 0.78/0.78
T. rubrum 25/50 12.5/100 12.5/50 −/− 12.5/- 6.25/200 6.25/6.25 25/50 12.5/100 50/100 100/100 0.31/0.31
E. floccosum (E 1423) 0.78/3.12 0.78/0.78 0.78/0.78 0.78/1.56 0.78/0.78 50/50 25/25 6.25/25 0.78/0.78 50/100 12.5/12.5 0.31/0.31
M. gypseum 12.5/12.5 25/100 12.5/50 50/- 25/- 200/- 50/100 12.5/25 25/50 100/100 −/− 1.56/1.56
M. audouinii 1.56/3.12 0.78/1.56 0.78/0.78 −/− 0.78/0.78 25/50 12.5/25 6.25/25 0.78/1.56 50/100 12.5/12.5 0.78/0.78
M. canis (CBS 113480) −/− 12.5/200 −/− 25/400 12.5/- 6.25/100 6.25/200 6.25/50 12.5/200 200/400 200/400 0.78/0.78
M. ferrugeneum (CBS 471.80) 0.78/1.56 0.78/0.78 0.78/0.78 0.78/1.56 0.78/0.78 25/- 1.56/1.56 0.78/3.12 0.78/0.78 100/100 25/50 0.31/0.31
T. violaceum (CBS 201.88) 12.5/50 3.12/100 3.12/50 6.25/- 6.25/- 12.5/200 100/- 1.56/- 6.25/50 25/100 1.56/100 0.31/0.78
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activity with compounds 10 and 11 being the less
efficient. In fact these last compounds are characterized
by the esterification of the carboxyl group (C-28) by 28-O-
[O-α-L-rhamnopyranosyl (1–4)-O-β-D-glucopyranosyl-(1–
6)-β-D-glucopyranosyl] (S5) and 28-O-[α-L-4-O-acetyl-rha
mnopyranosyl (1–4)-β-D-glucopyranosyl-(1–6)-β-D-gluco-
pyranosyl] (S6) respectively. This carboxyl group may play
an important role in their antifungal activities.
A number of studies have been carried out on the an-
tifungal activity of phenolic compounds from natural
sources [22]. It was the case of pinoresinol (3) that has
previously been described as fungicidal agent from Sam-
bucus williamsii [23] and Methyl atrarate (1) that showed
a good antifungal activity (MIC 6 μg/ml) on Candida albi-
cans [24]. Furthermore antifungal properties of phenolic
compounds may be due to iron deprivation or hydrogen
binding with vital proteins such as microbial enzymes
[25]. According to Hwang et al. [23], compound 3 may
depolarize or form pores in the fungal bilayer membrane.
These two compounds, different in size but with the same
number of hydroxyl groups were inactive on yeast and
possess almost the same antidermatophytic activities. It is
postulated that the site(s) and number of hydroxyl groups
of phenolic compounds are closely correlated to their anti-
microbial activities [22].
The broad range antidermatophytic activities of the
isolated compounds from P. fulvia explains the relatively
good in vitro and in vivo antidermatophytic activity of
the oil-moistened dichloromethane-methanol (1:1 v/v)
crude extract from this plant [6]. They can then serve as
markers for the standardization of antidermatophytic
phytomedicine from P. fulva.
Conclusion
The tested compounds showed a broad range of antider-
matophytic activities while only compounds 7 and 8
inhibited the growth of yeasts. Considering these results
and those from our previous studies on the crude extract,
these substances may be useful in the standardization of
antimicrobial and particularly antidermatophytic phyto-
medicine from P. fulva.
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